Evaluating for conversion disorder: When to suspect Creutzfeldt-Jakob disease
Current Psychiatry. 2010 November;09(11):78-83
November 1, 2010|Current Psychiatry
Author and Disclosure Information
Table 2
Distinguishing features of Creutzfeldt-Jakob disease
| Sporadic CJD | AD | DLBD | FTD-MND | |
|---|---|---|---|---|
| Time course | Rapid progression (median survival 4 to 5 months) | Insidious onset; progressive decline | Insidious onset; progressive decline | May experience rapid course to death |
| Age at onset | Age 50 to 70 | Incidence increases with age (usual onset age 65 to 85) | Older (age ~80) | Young age at onset |
| EEG findings | Periodic atypical triphasic waves; GPEDs | Normal or diffuse abnormalities | Rarely atypical triphasic waves | Increased slow activity, decreased fast activity |
| MRI findings | Restricted diffusion | Generalized atrophy | Generalized atrophy | Frontal atrophy |
| AD: Alzheimer’s disease; CJD: Creutzfeldt-Jakob disease; DLBD: diffuse Lewy body dementia; EEG: electroencephalography; FTD-MND: frontotemporal dementia with motor neuron disease; GPEDs: generalized periodic epileptiform discharges Source: References 7,8,19 | ||||
Related Resources
National Institute of Neurological Disorders and Stroke. Creutzfeldt-Jakob disease fact sheet. www.ninds.nih.gov/disorders/cjd/detail_cjd.htm.
Centers for Disease Control and Prevention. About CJD. www.cdc.gov/ncidod/dvrd/cjd.
Drug Brand Names
Chlorpromazine • Thorazine, Largactil
Quinacine • Atabrine
Disclosure
Dr. Gagliardi reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
